Oncolytic Virus Injection(RT-01)
Sponsors
Wuxi People's Hospital, The First Affiliated Hospital of Bengbu Medical University, The Affiliated Hospital of Xuzhou Medical University
Conditions
Advanced CancerAdvanced Solid TumorIntravenous InjectionSolid TumorT-cell LymphomaVirus
Phase 1
A Clinical Study of Intratumoral Administration of RT-01 in Patients With Advanced Solid Tumors
NCT05136937
Start: 2021-11-01End: 2023-06-01Target: 18Updated: 2022-01-31
A Study of Oncolytic Virus Injection (RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer
NCT05205421
Start: 2022-01-18End: 2024-01-31Target: 20Updated: 2022-08-05
A Study of Intratumoral Administration of Oncolytic Virus Injection (RT-01) in Patients With Advanced Solid Tumors
NCT05205408
Start: 2022-02-24End: 2024-06-30Target: 7Updated: 2022-11-29
A Study of Oncolytic Virus Injection (RT-01) in Combination With PD-1 Inhibitor in Patients With Advanced Solid Tumors
NCT05228119
Start: 2022-01-04End: 2023-10-01Target: 50Updated: 2022-05-09
Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma
NCT05387226
Start: 2022-05-31End: 2023-12-31Target: 6Updated: 2022-05-24